CD38 and Miyoshi myopathy: In December 2021, China has authorized the combined application of selinexor and dexamethasone as a treatment for patients with relapsed and refractory MM, these patients must have previously undergone treatment with at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38+ monoclonal antibody.